Edap Tms (NASDAQ:EDAP) Share Price Crosses Above 200-Day Moving Average – Here’s Why

Edap Tms S.A. (NASDAQ:EDAP) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.02 and traded as high as $4.39. Edap Tms shares last traded at $4.39, with a volume of 52,999 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on EDAP shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Edap Tms in a report on Monday, December 29th. Wall Street Zen raised shares of Edap Tms to a “hold” rating in a research report on Saturday, February 7th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.50.

Edap Tms Stock Performance

The company has a market capitalization of $164.15 million, a price-to-earnings ratio of -7.70 and a beta of -0.19. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.04. The stock has a 50-day simple moving average of $4.18 and a 200-day simple moving average of $3.02.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in EDAP. Financial Planning Navigators CORP bought a new stake in shares of Edap Tms in the 4th quarter worth about $33,000. Leonteq Securities AG bought a new position in shares of Edap Tms during the fourth quarter worth about $313,000. Kovack Advisors Inc. bought a new position in shares of Edap Tms during the fourth quarter worth about $53,000. Rock Springs Capital Management LP grew its stake in Edap Tms by 1.3% in the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider’s stock worth $4,233,000 after purchasing an additional 16,500 shares in the last quarter. Finally, Flax Pond Capital LLC acquired a new position in Edap Tms in the fourth quarter worth about $2,623,000. 62.74% of the stock is owned by institutional investors and hedge funds.

About Edap Tms

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.